CVRx announced new Category I CPT codes for Barostim therapy, enhancing reimbursement and adoption for heart failure treatment.
Quiver AI Summary
CVRx, Inc. announced that as of January 1, 2026, Category I Current Procedural Terminology (CPT) codes for baroreflex activation therapy using its Barostim device have replaced the previous Category III codes. These Category I codes are crucial for the adoption, coverage, and reimbursement of medical procedures in the U.S. healthcare system. CVRx believes this change will lead to more reliable reimbursement for healthcare providers and patients using the Barostim therapy, which is designed to improve symptoms in heart failure patients by using neuromodulation. The company encourages U.S. hospitals and physicians to update their billing systems accordingly. Barostim therapy is FDA-approved and has received Breakthrough Device designation for heart failure treatment. For more details, visit CVRx's website or their reimbursement guide.
Potential Positives
- CVRx has gained Category I CPT codes for its Barostim device, enhancing the likelihood of widespread adoption, coverage, and reimbursement in the U.S. healthcare system.
- The transition from Category III to Category I CPT codes is a significant validation of the Barostim therapy's importance in the treatment of heart failure.
- This change is expected to lead to more predictable and consistent reimbursement for healthcare professionals and patients using Barostim, potentially increasing its market penetration.
- Barostim is recognized as a pioneering device in neuromodulation therapy for heart failure, which may enhance CVRx's reputation and attract future investments or partnerships.
Potential Negatives
- The transition from Category III to Category I CPT codes indicates that prior coding was seen as less established, which may raise concerns about the prior acceptance and widespread use of Barostim therapy.
- The press release includes forward-looking statements about the impact of the new codes, emphasizing uncertainty regarding reimbursement and patient access, which may indicate potential challenges ahead for the company's financial outlook.
- The need for hospitals and physicians to update their billing systems could lead to confusion or disruptions in the short term, potentially affecting the adoption rates of Barostim procedures during the transition period.
FAQ
What are the new CPT codes for Barostim procedures?
The new Category I Current Procedural Terminology (CPT) codes for Barostim procedures became effective on January 1, 2026, replacing the previous Category III codes.
How do the new CPT codes affect Barostim reimbursement?
The new Category I CPT codes support more predictable and consistent reimbursement for Barostim patients and healthcare providers.
What is the significance of Barostim receiving Category I CPT codes?
Category I CPT codes indicate established medical procedures, enhancing the adoption, coverage, and reimbursement of Barostim therapy across the U.S. healthcare system.
How does Barostim therapy work?
Barostim is an implantable device that uses neuromodulation to improve heart failure symptoms by delivering electrical pulses to baroreceptors in the carotid artery.
Where can I find more information about Barostim?
More information about Barostim and its therapy can be found on the CVRx website at www.cvrx.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CVRX Insider Trading Activity
$CVRX insiders have traded $CVRX stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $CVRX stock by insiders over the last 6 months:
- & JOHNSON JOHNSON has made 0 purchases and 6 sales selling 62,569 shares for an estimated $637,001.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CVRX Hedge Fund Activity
We have seen 47 institutional investors add shares of $CVRX stock to their portfolio, and 40 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MARSHALL WACE, LLP removed 333,930 shares (-95.4%) from their portfolio in Q3 2025, for an estimated $2,694,815
- PARKMAN HEALTHCARE PARTNERS LLC removed 297,691 shares (-37.7%) from their portfolio in Q3 2025, for an estimated $2,402,366
- SCHONFELD STRATEGIC ADVISORS LLC removed 198,421 shares (-76.8%) from their portfolio in Q3 2025, for an estimated $1,601,257
- GOLDMAN SACHS GROUP INC added 122,201 shares (+153.0%) to their portfolio in Q3 2025, for an estimated $986,162
- MILLENNIUM MANAGEMENT LLC removed 96,439 shares (-29.8%) from their portfolio in Q3 2025, for an estimated $778,262
- BANK OF AMERICA CORP /DE/ added 91,376 shares (+102.6%) to their portfolio in Q3 2025, for an estimated $737,404
- SECTORAL ASSET MANAGEMENT INC removed 73,500 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $593,145
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CVRX Analyst Ratings
Wall Street analysts have issued reports on $CVRX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 11/06/2025
- Cantor Fitzgerald issued a "Overweight" rating on 08/05/2025
To track analyst ratings and price targets for $CVRX, check out Quiver Quantitative's $CVRX forecast page.
$CVRX Price Targets
Multiple analysts have issued price targets for $CVRX recently. We have seen 2 analysts offer price targets for $CVRX in the last 6 months, with a median target of $12.0.
Here are some recent targets:
- Ross Osborn from Cantor Fitzgerald set a target price of $13.0 on 11/06/2025
- William Plovanic from Canaccord Genuity set a target price of $11.0 on 11/06/2025
Full Release
MINNEAPOLIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, confirmed today that Category I Current Procedural Terminology (CPT) codes for baroreflex activation therapy using its Barostim device replaced the Category III codes as of Jan. 1, 2026. In the U.S. healthcare system, Category I CPT codes signify established procedures, supporting adoption, coverage, and reimbursement nationwide.
The new CPT codes for use with Barostim procedures are available in the reimbursement guide here , and on CVRx’s website.
U.S. hospitals and physicians performing Barostim procedures should update their billing systems and start using these new codes for all procedures performed on or after Jan. 1, 2026.
“We believe the new Category I CPT codes will enable more predictable and consistent reimbursement for Barostim patients and healthcare professionals,” said Kevin Hykes, President and Chief Executive Officer of CVRx, “and validate the important role of Barostim therapy in the heart failure treatment continuum.”
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit
www.cvrx.com
.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements regarding the anticipated effect the new codes will have on Barostim’s adoption are forward-looking statements. These statements speak only as of the date of this press release and are based on our current expectations and projections about the future and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause actual results to differ from our expectations, including the actual impact the new codes have on reimbursement and patient access. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
[email protected]
Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
[email protected]
